A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients.
Prostate cancer is the most common cancer among men in many countries, including the US and UK. About 1.5 million men are diagnosed worldwide each year.
The new drug has caused excitement as it is a type of treatment called immunotherapy. This approach uses the body’s own immune system to fight disease, and has already proved beneficial for some cancers.
Photo: Bloomberg
However, experts say it has not yet had the same impact on prostate cancer.
Now scientists have reported results from an early stage trial of an immunotherapy drug called VIR-5500, suggesting it could offer hope to men with advanced prostate cancer.
“We believe that such treatments may in the long term lead to cures,” said Johann de Bono of the Institute of Cancer Research and the Royal Marsden NHS foundation trust, who led the work.
VIR-5500was an engineered antibody that brought together the body’s killer T-cells with tumor cells trying to evade them, De Bono said.
This type of drug, called a T-cell engager, allowed the killer cells to wipe out the tumor ones.
The special feature of VIR-5500 was that it was designed to only become activated within the tumor, De Bono added.
This not only minimized side effects — an important consideration as other T-cell engagers have been found to trigger severe inflammatory responses in people with prostate cancer — but allowed the drug to linger in the bloodstream, meaning fewer doses might be needed.
Under the phase one clinical trial, funded by Vir Biotechnology, 58 men with advanced prostate cancer, and who had stopped responding to other treatments, were given VIR-5500.
The researchers found the majority of patients — 88 percent — experienced only very mild side effects.
Then, they looked at the level of prostate-specific antigen (PSA) in the men’s blood — a biomarker whereby higher levels can be a sign of prostate conditions.
De Bono said the trial started at low doses, with the dose increasing in stages.
When the team looked at data for 17 men given the highest dose, they found that for 14 (82 percent) their PSA level fell by at least half after treatment, nine (53 percent) saw their PSA level fall by at least 90 percent, and five (29 percent) experienced a fall of at least 99 percent.
De Bono described the results as unprecedented for a disease previously thought to be “immune-cold,” in other words resistant to immunotherapy.
The team added that, of 11 people given the highest dose and whose tumors were measurable, five showed tumor shrinkage. In one case involving a 63-year-old man whose cancer had spread to his liver, the team found 14 cancerous liver lesions “completely resolved” after six cycles of treatment.
The results, which have not yet been peer-reviewed, were presented at the American Society of Clinical Oncology genitourinary cancers symposium in San Francisco.
Further clinical trials are now being planned, De Bono said.
“We do need more data, but the results are stunning,” he said.
Imperial College London cancer biology professor Charlotte Bevan, who was not involved in the work, said an advance in using immunotherapy for prostate cancer was potentially very exciting, opening up a new class of drug.
However, it was important studies were carried out with people of different ethnicities, as there were disparities in prostate cancer outcomes, she said.
Prostate Cancer UK assistant director of research Simon Grieveson described the early-phase trial as exciting.
“With over 12,000 men dying from prostate cancer each year in the UK, we urgently need new and innovative ways to treat the disease,” he said. “These early results are extremely promising, with a number of men on the study responding positively to the treatment with minimal side effects. I look forward to seeing this now tested in larger trials, with the hope that this treatment will offer men more valuable time with their loved ones.”
An American scientist convicted of lying to US authorities about payments from China while he was at Harvard University has rebuilt his research lab in Shenzhen, China, to pursue technology the Chinese government has identified as a national priority: embedding electronics into the human brain. Charles Lieber, 67, is among the world’s leading researchers in brain-computer interfaces. The technology has shown promise in treating conditions such as amyotrophic lateral sclerosis and restoring movement in paralyzed people. It also has potential military applications: Scientists at the Chinese People’s Liberation Army have investigated brain interfaces as a way to engineer super soldiers by boosting
Indonesian police have arrested 13 people after shocking images of alleged abuse against small children at a daycare center went viral, sparking outrage across the nation, officials said on Monday. Police on Friday last week raided Little Aresha, a daycare center in Yogyakarta on Java island, following a report from a former employee. CCTV footage circulating on social media showed children, most younger than two, lying on the floor wearing only diapers, their hands and feet bound with rags. The police have confirmed that the footage is authentic. Police said they also found 20 children crammed into a room just 3m by 3m. “So
A grieving mother has ended her life at a clinic in Switzerland four years after the death of her only child. Wendy Duffy, 56, a physically healthy woman, died at the Pegasos clinic in Basel after struggling to cope with the death of her 23-year-old son, Marcus. The former care worker, from the West Midlands, England, had previously attempted to take her own life. The case comes as assisted dying would not become law in England and Wales after proposed legislation, branded “hopelessly flawed” by opponents, ran out of time. Ruedi Habegger, the founder of Pegasos, described Duffy’s death as
From post offices and parks to stations and even the summit of Mount Fuji, Japan’s vending machines are ubiquitous, but with the rapid pace of inflation cooling demand for their drinks, operators are being forced to rethink the business. Last month beverage giant DyDo Group Holdings announced it would remove about 20,000 vending machines — about 7 percent of their stock nationwide — by January next year, to “reconstruct a profitable network.” Pokka Sapporo Food & Beverage, based in Nagoya, also said last month it would sell its 40,000-machine operation to Osaka-based Lifedrink Co. “The strength of the vending machine
RSS